Ranbaxy Announces
Settlement Of Possible Imitrex ® Litigation With Glaxosmithkline
Posted AtRanbaxy.com
Ranbaxy Laboratories Limited
(Ranbaxy) announced today that it has settled all
matters relating to possible patent litigation with
GlaxoSmithKline relating to Sumatriptan Succinate
Tablets, the generic version of GlaxoSmithKline's
Imitrex ® Tablets.
The terms of the settlement,
provide that Ranbaxy may distribute a generic version
of Sumatriptan Succinate Tablets (in the 25 mg,50
mg and 100 mg strengths) in the United States with
an expected launch date in December, 2008.
Additional terms of the settlement
agreement were not disclosed.
The annual market sales for
Sumatriptan Succinate (Imitrex ®) were USD 985
million (IMS- MAT: Sept 2007).
Ranbaxy Laboratories Limited,
India's largest pharmaceutical company, is an integrated,
research based, international pharmaceutical company
producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and
patients across geographies. Ranbaxy’s continued
focus on R&D has resulted in several approvals
in developed markets and significant progress in New
Drug Discovery Research. The Company’s foray
into Novel Drug Delivery Systems has led to proprietary
"platform technologies," resulting in a
number of products under development. The Company
is serving its customers in over 125 countries and
has an expanding international portfolio of affiliates,
joint ventures and alliances, ground operations in
49 countries and manufacturing operations in 11 countries.
January 21, 2008 |
